{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:09:43Z","timestamp":1777349383392,"version":"3.51.4"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T00:00:00Z","timestamp":1691193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T00:00:00Z","timestamp":1691193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s10875-023-01560-1","type":"journal-article","created":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T07:03:11Z","timestamp":1691218991000},"page":"1754-1757","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Soluble Interleukin-2 Receptor\/White Blood Cell Ratio Reflects Granulomatous Disease Progression in Common Variable Immune Deficiency"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0698-4672","authenticated-orcid":false,"given":"Astrid C.","family":"van Stigt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5945-4435","authenticated-orcid":false,"given":"Virgil A. S. H.","family":"Dalm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole M. A.","family":"Nagtzaam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. Martin","family":"van Hagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willem A.","family":"Dik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7061-5321","authenticated-orcid":false,"given":"Hanna","family":"IJspeert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,5]]},"reference":[{"key":"1560_CR1","doi-asserted-by":"publisher","first-page":"1190235","DOI":"10.3389\/fimmu.2023.1190235","volume":"14","author":"HM Bintalib","year":"2023","unstructured":"Bintalib HM, van de Ven A, Jacob J, Davidsen JR, Fevang B, Hanitsch LG, et al. Diagnostic testing for interstitial lung disease in common variable immunodeficiency: a systematic review. Front Immunol. 2023;14:1190235.","journal-title":"Front Immunol"},{"issue":"5","key":"1560_CR2","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.anai.2017.01.004","volume":"118","author":"S Hartono","year":"2017","unstructured":"Hartono S, Motosue MS, Khan S, Rodriguez V, Iyer VN, Divekar R, et al. Predictors of granulomatous lymphocytic interstitial lung disease in common variable immunodeficiency. Ann Allergy Asthma Immunol. 2017;118(5):614\u201320.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1560_CR3","doi-asserted-by":"publisher","first-page":"627423","DOI":"10.3389\/fimmu.2021.627423","volume":"12","author":"F Cinetto","year":"2021","unstructured":"Cinetto F, Scarpa R, Carrabba M, Firinu D, Lougaris V, Buso H, et al. Granulomatous lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID): a multicenter retrospective study of patients from Italian PID Referral Centers. Front Immunol. 2021;12:627423.","journal-title":"Front Immunol"},{"issue":"6","key":"1560_CR4","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.jaip.2015.07.004","volume":"3","author":"PJ Maglione","year":"2015","unstructured":"Maglione PJ, Overbey JR, Cunningham-Rundles C. Progression of common variable immunodeficiency interstitial lung disease accompanies distinct pulmonary and laboratory findings. J Allergy Clin Immunol Pract. 2015;3(6):941\u201350.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"1560_CR5","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s10875-020-00908-1","volume":"41","author":"RM Berbers","year":"2021","unstructured":"Berbers RM, Drylewicz J, Ellerbroek PM, van Montfrans JM, Dalm V, van Hagen PM, et al. Targeted proteomics reveals inflammatory pathways that classify immune dysregulation in common variable immunodeficiency. J Clin Immunol. 2021;41(2):362\u201373.","journal-title":"J Clin Immunol"},{"issue":"7","key":"1560_CR6","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s10875-022-01318-1","volume":"42","author":"MSA Fraz","year":"2022","unstructured":"Fraz MSA, Michelsen AE, Moe N, Aalokken TM, Macpherson ME, Nordoy I, et al. Raised serum markers of T cell activation and exhaustion in granulomatous-lymphocytic interstitial lung disease in common variable immunodeficiency. J Clin Immunol. 2022;42(7):1553\u201363.","journal-title":"J Clin Immunol"},{"issue":"2","key":"1560_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jaip.2014.09.019","volume":"3","author":"J Vitale","year":"2015","unstructured":"Vitale J, Convers KD, Goretzke S, Guzman M, Noyes B, Parkar N, et al. Serum IL-12 and soluble IL-2 receptor levels as possible biomarkers of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency: a case report. J Allergy Clin Immunol Pract. 2015;3(2):273\u20136.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1560_CR8","doi-asserted-by":"publisher","unstructured":"Smits B, Goldacker S, Seneviratne S, Malphettes M, Longhurst H, Mohamed OE, et al. The efficacy and safety of systemic corticosteroids as first line treatment for granulomatous lymphocytic interstitial lung disease. J Allergy Clin Immunol. 2022. https:\/\/doi.org\/10.1016\/j.jaci.2022.12.813","DOI":"10.1016\/j.jaci.2022.12.813"},{"issue":"3","key":"1560_CR9","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1007\/s10875-020-00947-8","volume":"41","author":"AC van Stigt","year":"2021","unstructured":"van Stigt AC, Dalm V, Nagtzaam NMA, van Rijswijk DA, Barendregt BH, van Hagen PM, et al. Soluble interleukin-2 receptor is a promising serum biomarker for granulomatous disease in common variable immune deficiency. J Clin Immunol. 2021;41(3):694\u20137.","journal-title":"J Clin Immunol"},{"issue":"5","key":"1560_CR10","doi-asserted-by":"publisher","first-page":"e0233811","DOI":"10.1371\/journal.pone.0233811","volume":"15","author":"E Mavropoulou","year":"2020","unstructured":"Mavropoulou E, Mechie NC, Knoop R, Petzold G, Ellenrieder V, Kunsch S, et al. Association of serum interleukin-6 and soluble interleukin-2-receptor levels with disease activity status in patients with inflammatory bowel disease: a prospective observational study. PLoS ONE. 2020;15(5):e0233811.","journal-title":"PLoS ONE"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-023-01560-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-023-01560-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-023-01560-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T10:30:50Z","timestamp":1700476250000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-023-01560-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,5]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1560"],"URL":"https:\/\/doi.org\/10.1007\/s10875-023-01560-1","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,5]]},"assertion":[{"value":"5 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The study was approved by the medical ethical committee of Erasmus MC (MEC-2013-026, MEC-2021-0652, MEC-2021-0251, MEC-2019-0839).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}